IUPAC Name: (2S,3R,4S,5S,6R)-3-Fluoranyl-6-(hydroxymethyl)oxane-2,4,5-triol
Canonical SMILES: C(C1C(C(C(C(O1)O)F)O)O)O
Isomeric SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)[18F])O)O)O
InChI: InChI=1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2/t2-,3-,4-,5-,6+/m1/s1/i7-1
InChIKey: ZCXUVYAZINUVJD-AHXZWLDOSA-N
Molecular Weight: 181.149478 [g/mol]
Molecular Formula: C₆H₁₁FO₅
XLogP3-AA: -1.6
H-Bond Donor: 4
H-Bond Acceptor: 6 
Index of Refraction: 1.535
Molar Refractivity: 35.66 cm³
Molar Volume: 114.4 cm³
Surface Tension: 67.5 dyne/cm
Density: 1.59 g/cm³ 
Melt. point: 170–176 °C (338–349 °F)
Classification Code of Fludeoxyglucose F 18 (CAS NO.105851-17-0): Diagnostic aid; Radioactive agent; Radiopharmaceuticals

In the 1970s, Tatsuo Ido and Al Wolf at the Brookhaven National Laboratory were the first to describe the synthesis of ¹⁸F-FDG. The compound was first administered to two normal human volunteers by Abass Alavi in August, 1976 at the University of Pennsylvania. Brain images obtained with an ordinary (non-PET) nuclear scanner demonstrated the concentration of ¹⁸F-FDG in that organ.

 Fludeoxyglucose F 18 (CAS NO.105851-17-0) is a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET). Chemically, it is 2-Deoxy-2-(¹⁸F)fluoro-D-glucose, a glucose analog, with the positron-emitting radioactive isotope Fluorine-18 substituted for the normal hydroxyl group at the 2' position in the glucose molecule. In PET imaging, it can be used for the assessment of glucose metabolism in the heart, lungs, and the brain. It is also used for imaging tumours in oncology, where usually dynamic images are analysed in terms of Standardized Uptake Values. It has also been approved for use in diagnosing Alzheimer's disease.

  Fludeoxyglucose F 18 (CAS NO.105851-17-0), its Synonyms are alpha-D-Glucopyranose, 2-deoxy-2-(fluoro-(sup 18)F)- ; 18FDG ; 2-(Fluoro-18F)-2-deoxy-alpha-glucopyranose ; 2-Deoxy-2-fluoro-(sup 18)F-alpha-D-glucopyranose ; F-18 FDG ; Fludeoxyglucose (18F) .